Skip to main content
Premium Trial:

Request an Annual Quote

Chinese Regulators Approve AmoyDx's ALK, ROS1 Gene Fusion Detection Kits

NEW YORK (GenomeWeb) – Chinese molecular diagnostics firm Amoy Diagnostics this week announced it has received regulatory approval from the China Food and Drug Administration for two in vitro diagnostics kits.

The firm also said that the kits obtained CE marking in Europe.

The AmoyDx ROS1 Kit detects 14 ROS1 gene fusions, while the AmoyDx ALK/ROS1 Kit detects 26 ALK gene fusions and 14 ROS1 gene fusions. The kits use real-time PCR technology to analyze tumor messenger RNA from human tumor tissue or body fluids, and can provide results within 2.5 hours on most commercially available real-time PCR instruments.

The company has been working with drug developer OxOnc Development since August 2013 to provide the ROS1 gene fusion detection kit as a companion diagnostic for a pivotal clinical trial for Pfizer's ALK- and ROS1-inhibitor Xalkori (crizotinib) being conducted in the Asia-Pacific region, including China, Taiwan, Japan, and South Korea.

Along with its previous CFDA-approved EGFR mutation detection kit for clinical use, Amoy is getting closer to "real panel testing of relevant molecular biomarkers for currently available target therapies," Amoy Executive Vice President Mike Zhu said in a statement.

Chinese regulators approved the EGFR kit in 2010, the same year that the CFDA approved Amoy's KRAS detection kit. In March 2013 the agency approved Amoy's EML4-ALK Fusion Gene Detection Kit.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.